GH Research plc

Aardvark Therapeutics’ drug candidates are designed to reduce hunger, but the company worked up enough of an appetite among investors to support the company’s initial public offering – the fifth bioph

GH Research PLC reported positive Phase IIb data on 3 February for GH-001 (mebufotenin), an inhalation formulation of the psychedelic compound synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), i

Lykos Therapeutics is not taking the rejection of midomafetamine lying down. The company said late on 9 August that the product, a version of the illicit drug MDMA for the treatment of post-traumatic

The failure of NRx Pharmaceuticals, Inc. ’s NRX-101 in suicidal bipolar depression at the end of April highlights the difficulty of treating this intractable condition. The company is still moving fo